DE69306063D1 - Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese - Google Patents

Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese

Info

Publication number
DE69306063D1
DE69306063D1 DE69306063T DE69306063T DE69306063D1 DE 69306063 D1 DE69306063 D1 DE 69306063D1 DE 69306063 T DE69306063 T DE 69306063T DE 69306063 T DE69306063 T DE 69306063T DE 69306063 D1 DE69306063 D1 DE 69306063D1
Authority
DE
Germany
Prior art keywords
oxothiazolidine
medicament
manufacture
carboxylate esters
intracellular glutathione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69306063T
Other languages
English (en)
Other versions
DE69306063T2 (de
Inventor
W Bruce Rowe
Dennis L Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25462874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69306063(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Publication of DE69306063D1 publication Critical patent/DE69306063D1/de
Application granted granted Critical
Publication of DE69306063T2 publication Critical patent/DE69306063T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69306063T 1992-08-20 1993-04-23 Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese Revoked DE69306063T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/932,761 US5208249A (en) 1992-08-20 1992-08-20 Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate

Publications (2)

Publication Number Publication Date
DE69306063D1 true DE69306063D1 (de) 1997-01-02
DE69306063T2 DE69306063T2 (de) 1997-05-22

Family

ID=25462874

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69306063T Revoked DE69306063T2 (de) 1992-08-20 1993-04-23 Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese

Country Status (7)

Country Link
US (1) US5208249A (de)
EP (1) EP0583863B1 (de)
JP (1) JPH06183973A (de)
AU (1) AU666931B2 (de)
CA (1) CA2096036C (de)
DE (1) DE69306063T2 (de)
ES (1) ES2094479T3 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0715853A1 (de) * 1991-01-10 1996-06-12 Transcend Therapeutics, Inc. Verwendung von Glutathionester zur Behandlung von Lungenerkrankungen
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
EP0656201A1 (de) * 1993-11-09 1995-06-07 Transcend Therapeutics, Inc. Verwendung von glutathionsynthesefordernden Substanzen als Haarwuchsmittel
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
FR2742658B1 (fr) * 1995-12-22 1998-01-30 Oreal Utilisation de la procysteine comme agent depigmentant
FR2742750B1 (fr) 1995-12-22 1998-01-30 Oreal Nouveaux derives de l'acide l-2-oxothiazolidine 4-carboxylique et leur utilisation pour le soin de la peau
FR2751331A1 (fr) * 1996-07-18 1998-01-23 Oreal Nouveau derive de l'acide kojique et son utilisation comme agent depigmentant
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
US6013632A (en) * 1997-01-13 2000-01-11 Emory University Compounds and their combinations for the treatment of influenza infection
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
CA2350715A1 (en) * 1999-08-09 2001-04-12 Webb-Waring Institute For Biomedical Research A method for the treatment of ocular oxidative stress
WO2001012166A2 (en) * 1999-08-17 2001-02-22 University Of Saskatchewan Technologies Inc. Improved treatment for acute physical insult to the central nervous system
FR2816838B1 (fr) * 2000-11-17 2004-12-03 Oreal Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants
US20020137779A1 (en) * 2001-02-14 2002-09-26 Advanced Biochemicals Inc. Use of L-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes
ES2367258T3 (es) * 2002-04-19 2011-10-31 Arizona Board Of Regents On Behalf Of The University Of Arizona Métodos para modular la fototoxicidad.
US7022317B2 (en) 2003-04-25 2006-04-04 L'oreal Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents
FR2854160B1 (fr) * 2003-04-25 2005-06-17 Oreal Nouveaux derives heterocycliques de l'acide 2-oxothiazolidine4-carboxylique, utilisation comme agent de photoprotection active
FR2877004B1 (fr) * 2004-10-21 2007-03-09 Oreal Esters et amides silaniques d'acide 2-oxothiazolidine-4- carboxylique et leurs utilisations cosmetiques.
CN100434062C (zh) * 2006-08-28 2008-11-19 卢小明 L-2-氧代硫氮杂戍环烷-4-羧酸及其酯类衍生物作为皮肤药妆品的应用
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10626364B2 (en) 2015-07-30 2020-04-21 Merck Patent Gmbh Method for increasing the glutathione level in cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
ATE119038T1 (de) * 1988-12-09 1995-03-15 Allergan Inc Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt.
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
AU5040493A (en) * 1992-11-30 1994-06-09 Transcend Therapeutics, Inc Method for treating systemic inflammatory response syndrome

Also Published As

Publication number Publication date
EP0583863B1 (de) 1996-11-20
JPH06183973A (ja) 1994-07-05
DE69306063T2 (de) 1997-05-22
US5208249A (en) 1993-05-04
CA2096036A1 (en) 1994-02-21
CA2096036C (en) 1999-04-27
AU3718193A (en) 1994-02-24
EP0583863A1 (de) 1994-02-23
ES2094479T3 (es) 1997-01-16
AU666931B2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
DE69306063T2 (de) Verwendung von L-2-Oxothiazolidin-4-Carboxylatestern zur Herstellung eines Arzneimittels zur Stimulierung der intracellulären Glutathionsynthese
ATA68386A (de) Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten
DE68928783D1 (de) Zwischenverbindungen zur Herstellung von Fungiziden
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE69631157D1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes
DE9415020U1 (de) Filtereinheit zur Herstellung von Filterkaffee
ATE198275T1 (de) Subkutane implantate bestehend aus nomgestrolderivaten
DE68924714T2 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
ATA145388A (de) Verwendung von selenmethionin zur herstellung eines arzneimittels
DE69125489D1 (de) Verwendung von derivaten durch menschliches gallensalz stimulierter lipase zur herstellung von medikamenten
DE69103865D1 (de) Verwendung von tetrahydro-isoquinoline-derivate zur herstellung eines arzneimittels mit antitumoraler wirkung.
DE69005978D1 (de) Verwendung von Actinonin zur Herstellung eines Medikamentes zur Inhibierung der Angiogenese.
DE69313316T2 (de) Verwendung von Oxazopyrrolochinolinen und Pyrrolochinolonchinonen zur Herstellung von Produktionsbeschleunigern von Nervenwachstumsfaktoren g
DE69323137T2 (de) Vorrichtung zur Defibrillation des Herzens
DE68905657T2 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE58905133D1 (de) Verwendung eines goldbades zur herstellung von zahnersatz.
DE69431097T2 (de) Verfahren zur Herstellung von humanem Serumalbumin
DE69119896D1 (de) Neue verwendung von bambuterol
DE69402241D1 (de) Verwendung von 2-Acetylpyridine zur Herstellung eines Arzneimittles zur Unterdrückung des Rauchens
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69228235T2 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE69121210D1 (de) Therapeutische verwendung des fibroblastenwachstumsfaktors
DE59203472D1 (de) Verwendung von dl-valin, dessen estern und/oder salzen zur bekämpfung von kopfschuppen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation